Literature DB >> 33507217

Analysis of Pathogenic Variants Correctable With CRISPR Base Editing Among Patients With Recessive Inherited Retinal Degeneration.

Lewis E Fry1,2, Michelle E McClements1,2, Robert E MacLaren1,2.   

Abstract

Importance: Many common inherited retinal diseases are not easily treated with gene therapy. Gene editing with base editors may allow the targeted repair of single-nucleotide transition variants in DNA and RNA. It is unknown how many patients have pathogenic variants that are correctable with a base editing strategy. Objective: To assess the prevalence and spectrum of pathogenic single-nucleotide variants amenable to base editing in common large recessively inherited genes that are associated with inherited retinal degeneration. Design, Setting, and Participants: In this retrospective cross-sectional study, nonidentifiable records of patients with biallelic pathogenic variants of genes associated with inherited retinal degeneration between July 2013 and December 2019 were analyzed using data from the Oxford University Hospitals Medical Genetics Laboratories, the Leiden Open Variation Database, and previously published studies. Six candidate genes (ABCA4, CDH23, CEP290, EYS, MYO7A, and USH2A), which were determined to be the most common recessive genes with coding sequences not deliverable in a single adeno-associated viral vector, were examined. Data were analyzed from April 16 to May 11, 2020. Main Outcomes and Measures: Proportion of alleles with a pathogenic transition variant that is potentially correctable with a base editing strategy and proportion of patients with a base-editable allele.
Results: A total of 12 369 alleles from the Leiden Open Variation Database and 179 patients who received diagnoses through the genetic service of the Oxford University Hospitals Medical Genetics Laboratories were analyzed. Editable variants accounted for 53% of all pathogenic variants in the candidate genes contained in the Leiden Open Variation Database. The proportion of pathogenic alleles that were editable varied by gene; 63.1% of alleles in ABCA4, 62.7% of alleles in CDH23, 53.8% of alleles in MYO7A, 41.6% of alleles in CEP290, 37.3% of alleles in USH2A, and 22.2% of alleles in EYS were editable. The 5 most common editable pathogenic variants of each gene accounted for a mean (SD) of 19.1% (9.5%) of all pathogenic alleles within each gene. In the Oxford cohort, 136 of 179 patients (76.0%) had at least 1 editable allele. A total of 53 of 107 patients (49.5%) with biallelic pathogenic variants in the gene ABCA4 and 16 of 56 patients (28.6%) with biallelic pathogenic variants in the gene USH2A had 1 of the 5 most common editable alleles. Conclusions and Relevance: This study found that pathogenic variants amenable to base editing commonly occur in inherited retinal degeneration. These findings, if generalized to other cohorts, provide an approach for developing base editing therapies to treat retinal degeneration not amenable to gene therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33507217      PMCID: PMC7844696          DOI: 10.1001/jamaophthalmol.2020.6418

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  9 in total

1.  Genotypes Influence Clinical Progression in EYS-Associated Retinitis Pigmentosa.

Authors:  Jui-En Lo; Chia-Yi Cheng; Chang-Hao Yang; Chung-May Yang; Yi-Chieh Chen; Yu-Shu Huang; Pei-Lung Chen; Ta-Ching Chen
Journal:  Transl Vis Sci Technol       Date:  2022-07-08       Impact factor: 3.048

Review 2.  Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.

Authors:  Wenyi Liu; Luoxi Li; Jianxin Jiang; Min Wu; Ping Lin
Journal:  Precis Clin Med       Date:  2021-07-10

Review 3.  Therapy Approaches for Stargardt Disease.

Authors:  Elena Piotter; Michelle E McClements; Robert E MacLaren
Journal:  Biomolecules       Date:  2021-08-09

4.  Evaluation of photoreceptor-directed fibroblasts derived from retinitis pigmentosa patients with defects in the EYS gene: a possible cost-effective cellular model for mechanism-oriented drug.

Authors:  Dilip Rai; Masaki Iwanami; Yoriko Takahashi; Yukari Komuta; Noriyuki Aoi; Akihiro Umezawa; Yuko Seko
Journal:  Stem Cell Res Ther       Date:  2022-04-11       Impact factor: 6.832

Review 5.  The Scope of Pathogenic ABCA4 Mutations Targetable by CRISPR DNA Base Editing Systems-A Systematic Review.

Authors:  Elena Piotter; Michelle E McClements; Robert E MacLaren
Journal:  Front Genet       Date:  2022-01-27       Impact factor: 4.599

Review 6.  Prime Editing for Inherited Retinal Diseases.

Authors:  Bruna Lopes da Costa; Sarah R Levi; Eric Eulau; Yi-Ting Tsai; Peter M J Quinn
Journal:  Front Genome Ed       Date:  2021-11-25

7.  Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids.

Authors:  Michelle E McClements; Hannah Steward; William Atkin; Emily Archer Goode; Carolina Gándara; Valeria Chichagova; Robert E MacLaren
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.283

Review 8.  New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome.

Authors:  Lauren Major; Michelle E McClements; Robert E MacLaren
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

9.  In Silico Analysis of Pathogenic CRB1 Single Nucleotide Variants and Their Amenability to Base Editing as a Potential Lead for Therapeutic Intervention.

Authors:  Julia-Sophia Bellingrath; Michelle E McClements; Maria Kaukonen; Manuel Dominik Fischer; Robert E MacLaren
Journal:  Genes (Basel)       Date:  2021-11-27       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.